10.5% CAGR | Drug Discovery Informatics Market Expansion: Anticipated To Reach USD 7.9 Billion By 2032

According to the report, the "drug discovery informatics market" was valued at $2.9 billion in 2022, and is estimated to reach $7.9 billion by 2032, growing at a CAGR of 10.5% from 2023 to 2032. 

The Drug Discovery Informatics Market is expected to grow with a significant CAGR during the analysis period mainly due to rise in chronic diseases and the advent of new powerful tools such as AI and big data. However, challenges such as inflation, supply chain issues and expiring patents might restrain the market growth.

Drug discovery informatics utilizes computational and informational method to expedite the discovery as well as advancement of novel pharmaceuticals. This method utilizes diverse computational techniques, algorithms, and databases to analyze biological data, forecast drug-target interactions, refine drug candidates, and enhance the efficiency of the drug development journey.

The key factors that drive drug discovery informatics market growth are the rise in the prevalence of chronic diseases such as cancer, cardiovascular diseases, diabetes, high blood pressure, and various others, the rise in R&D activities for drug discovery, and the surge in demand for target drug therapy. For instance, according to the report published by IQVIA in June 2022, it has been estimated that oncology trial starts reached historically high levels in 2021, up 56% from 2016 and mostly focused on rare cancer indications. 

Request Sample of the Report on Drug Discovery Informatics Market Forecast 2032: https://www.alliedmarketresearch.com/request-sample/A07074 

Drug Discovery Informatics Market Statistics:

• Drug discovery segment is expected to grow with a CAGR of 10.7% during the forecast period.
• The sequencing and target data analysis segment is expected to register a faster CAGR of 11.1% during the analysis period.
• The pharmaceutical companies is expected to grow with a higher CAGR of 10.8% during forecast period.
• Sequencing and target data analysis segment acquired major share in the global Drug Discovery Informatics Industry in 2022.
• North America to maintain its dominance by 2032

Recession Impact

• During a recession, governments, academic institutions, and private funding sources might decrease investment in research and development (R&D) projects, including drug discovery initiatives. This reduction in funding can limit the resources available for conducting research, acquiring new technologies, and hiring skilled personnel.
• Further, pharmaceutical companies may reassess their R&D priorities and allocate resources to drug discovery programs with potentially higher returns on investment or greater market demand. This shift in focus could lead to increased investment in certain therapeutic areas, such as infectious diseases or chronic conditions, while reducing investment in others.

Connect to our Analyst – https://www.alliedmarketresearch.com/connect-to-analyst/A07074

Drug Discovery Informatics Market Report Highlights:

By Application

• Drug Discovery
• Drug Development

By Function

• Sequencing and Target Data Analysis
• Library and Database Preparation
• Docking
• Molecular Modelling
• Others

By End User

• Biotechnology Companies
• Pharmaceutical Companies
• Contract Research Organizations
• Other End Users

By Region

• North America (U.S., Canada, Mexico)
• Europe (Germany, France, UK, Italy, Spain, Rest of Europe)
• Asia-Pacific (Japan, China, Australia, India, South Korea, Rest of Asia-Pacific)
• LAMEA (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)

Leading Market Players:

• Certara
• Boehringer Ingelheim International GmbH
• Infosys Ltd.
• Charles River Laboratories
• Collaborative Drug Discovery, Inc.
• Eurofins DiscoverX Products
• Jubilant Biosys
• Selvita
• Novo Informatics Pvt. Ltd.
• ChemAxon Ltd.
• Albany Molecular Research Inc.
• Oracle
• Accenture
• Agilent Technologies, Inc.
• Illumina, Inc.

Request Customization:

https://www.alliedmarketresearch.com/request-for-customization/A07074

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.